USP Delivers End-to-End Supply Chain Visibility

June 9, 2026 - The United States Pharmacopeia (USP) published its Annual Drug Shortages Report on June 9, 2026. For the first time, the report incorporates upstream data on Key Starting Materials (KSMs), revealing that geographic concentration of critical pharmaceutical ingredients begins far earlier than previously understood.

The findings are sobering: the average duration of a drug shortage has grown to over 5 years, up from 4.3 years in 2024 and roughly 2 years in 2019. Product discontinuations surged 60 percent from 2024 to 2025. Active drug shortages in the U.S. reached 223 in Q1 2026.

44 Percent of Shortage Drugs Depend on Single-Country KSMs

USP found that 44 percent of drugs in shortage have at least one KSM manufactured exclusively in a single country, typically China or India. This concentration risk means a disruption at a single facility can cascade across every downstream manufacturer.

Matthew Christian, Director of Supply Chain Insights at USP, stated: Manufacturers of generic drugs and their ingredients operate on thin, sometimes unsustainable margins. This report shows a relationship between prices received by manufacturers and continued production.

Discontinuations Driven by Low Prices

The 60 percent surge in discontinuations represents a market failure. USP confirms that the price of discontinued medicines fell before exit. The pattern is acute in sterile injectables, which account for 71 percent of all shortages.

This creates opportunity for API suppliers that can manufacture reliably at moderate cost. As incumbents exit low-margin products, the supply vacuum must be filled by new entrants.

External Shocks Compound Structural Vulnerabilities

USP identifies four shortage drivers: low prices, manufacturing complexity, geographic concentration, and quality concerns. These structural risks are amplified by external shocks including petrochemical feedstock disruptions and geopolitical tensions.

For API suppliers, the convergence creates an environment where supply reliability commands premium pricing. Companies demonstrating diversified, resilient supply chains are positioned to capture market share.

Strategic Opportunities for B2B Suppliers

• KSM Diversification: Suppliers offering key starting materials from multiple geographies directly address the 44 percent single-country risk.
• Low-Margin Product Entry: As incumbents exit discontinuation-prone products, efficient manufacturers can capture newly available market share.
• Sterile Injectables Capacity: With 71 percent of shortages in sterile injectables, CDMOs with fill-finish capacity hold significant competitive advantage.
• Quality Systems: GMP compliance investments can differentiate suppliers in a quality-conscious market.
• Strategic Inventory: The 5-year shortage duration suggests buffer stocks for critical intermediates may replace just-in-time models.

Policy Response and Market Outlook

Anthony Lakavage, USP Executive VP, called for urgent action: Todays market does not reward resilience. Policymakers must establish benchmarks for supply reliability.

The BIOSECURE Act, FDA PreCheck Pilot Program, and state-level initiatives create frameworks favoring diversified suppliers. The era of competing solely on price is ending. The market is pricing in supply reliability, geographic diversification, and quality consistency.

For procurement teams, USP Medicine Supply Map provides real-time visibility into supply chain vulnerabilities. Companies seeking to diversify API sourcing should prioritize partnerships with suppliers demonstrating geographic redundancy.